Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glioblastoma mutliforme

- PMLiVE

Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC

Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection

- PMLiVE

Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours

The new formulation reduces administration time from 30-to-60 minutes to three-to-five minutes

- PMLiVE

BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

- PMLiVE

BMS receives FDA approval for immunotherapy combination in liver cancer

Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

- PMLiVE

BMS granted FDA approval for immunotherapy combination in colorectal cancer

More than 154,000 cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

BMS receives positive CHMP opinion for perioperative Opdivo regimen in lung cancer

Up to 55% of non-metastatic NSCLC patients will develop disease recurrence despite surgical resection

- PMLiVE

BMS granted EC approval for immunotherapy combination in liver cancer

More than 866,100 cases of the disease were diagnosed globally in 2022

- PMLiVE

BMS shares overall survival results for Opdivo in phase 3 lung cancer trial

More than 200,000 people are diagnosed with lung cancer in the US every year

- PMLiVE

BMS receives CHMP recommendation for Opdivo/Yervoy combination in liver cancer

Hepatocellular carcinoma accounts for approximately 90% of all liver cancer cases globally

- PMLiVE

BMS presents promising data for immunotherapy combination in phase 3 colorectal cancer trial

Over 154,000 cases of colorectal cancer are expected to be diagnosed in the US in 2025

- PMLiVE

Bristol Myers Squibb’s injectable Opdivo formulation granted FDA approval

Opdivo Qvantig can be administered in three to five minutes compared to 30 minutes for the drug’s IV form

- PMLiVE

Bristol Myers Squibb’s Opdivo regimen granted FDA approval in NSCLC

More than 200,000 people are diagnosed with lung cancer in the US every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links